evipedia.ai
← Back

Protandim for Health & Longevity

Evidence Review created on 09/13/2026 using AI4L / Opus 5

Also known as: Protandim Nrf2 Synergizer, Nrf2 Synergizer, LifeVantage Protandim, Milk Thistle, Silybum marianum, Silymarin, Bacopa, Bacopa monnieri, Ashwagandha, Withania somnifera, Green Tea Extract, Camellia sinensis, EGCG, Turmeric, Curcuma longa, Curcumin

Motivation

Protandim is an oral supplement that blends extracts of five plants — milk thistle, bacopa, ashwagandha, green tea and turmeric — into a single daily dose. Vitamin C and vitamin E neutralize damaging molecules one at a time. This blend was designed differently: to switch on the genes that let cells build their own protective enzymes. That idea — nudging internal defenses rather than supplying a substitute — draws attention from people focused on slowing biological aging.

The formula was patented in the early 2000s and is sold worldwide through a direct-selling company. It has gathered an unusual mix of attention. A government aging-research program reported that the blend lengthened the lives of male mice. Regulators have challenged the disease claims made around it. Independent trials in people have been few and small, and much of the supporting laboratory work came from scientists tied to the manufacturer.

This review examines what the published record shows: how the blend is supposed to work, what it has and has not changed in people, how the amount of each plant compares with the amounts studied separately, what risks the literature describes, and how the supporting evidence was produced and by whom.

Benefits - Risks - Protocol - Conclusion

Sources below give a high-level view of what the blend does in people and in animals, of the NRF2 pathway (the cellular switch that turns on the body’s own protective enzymes) it targets, and of the debate over how much the findings mean.

Two of the six priority platforms carry qualifying content — the FoundMyFitness and Chris Kresser episodes above, which earn their places through the shared pathway rather than by naming the blend. Peter Attia, Andrew Huberman, Life Extension and Lifespan.io host nothing on this intervention or its pathway at sufficient depth, so the remaining three slots are drawn from primary research. Five items are listed, each qualifying on its own merits rather than to reach the count.

Grokipedia

  • Protandim

    Traces the blend from its patent through the NRF2 synergy claim, the trial record, the 2017 regulatory action and the multi-level marketing model in one place, with the commercial history covered at unusual length.

Examine

No Examine article on Protandim exists. Examine indexes single compounds rather than branded proprietary blends; its pages on milk thistle, bacopa, ashwagandha, green tea catechins and curcumin cover the individual ingredients instead.

ConsumerLab

  • What is Protandim and does it really work?

    The only independent source that publishes the per-ingredient milligram amounts hidden inside the proprietary blend, alongside a short appraisal of the two human trials and the 2012 metal-fragment recall.

Systematic Reviews

No systematic review or meta-analysis covers the blend itself; the papers below each pool trials of one ingredient, at doses generally above what the blend delivers.

Mechanism of Action

Protandim targets one pathway: NRF2 (nuclear factor erythroid 2–related factor 2). At rest, KEAP1 (a sensor protein) holds NRF2 outside the nucleus and tags it for disposal. Mildly reactive plant compounds — silymarin, bacosides, withaferin A, epigallocatechin-3-gallate (EGCG, the main green tea catechin) and curcumin, one from each plant — modify KEAP1’s sulfur-containing sites, freeing NRF2 to bind the antioxidant response element, a DNA switch upstream of protective genes. The enzymes produced — superoxide dismutase (SOD), catalase and heme oxygenase-1 (HO-1) — dispose of damaging molecules.

The agents are given together for synergy rather than addition. Each sits far below its individually studied dose; the rationale is that several weak activators pressing one switch outdo the sum of the parts while avoiding each compound’s own pharmacology. In cultured cells the five together induced HO-1 three- to nine-fold (Velmurugan et al., 2009).

Co-administration has its own consequences: all five are poorly absorbed and heavily conjugated in gut and liver by the UGT and SULT enzyme families (which tag them for excretion), competing for the same routes and raising each other’s exposure. Plasma half-lives are short — 2–8 hours for curcumin and silymarin, 3–5 hours for the catechins — while the induction they trigger lasts far longer. In rats its catechin, silibinin and curcumin concentrated in the small intestine without accumulating on repeat dosing (Song et al., 2019). The competing reading: cell-culture activation says little about people, since blood levels after a 675 mg dose fall far below those used in dishes.

Historical Context & Evolution

The five plants were not developed together. Milk thistle has been used for liver complaints since antiquity, ashwagandha and bacopa are Ayurvedic remedies, and green tea and turmeric are dietary staples. Their original intended uses were traditional and single-plant, with no connection to aging.

The blend itself was assembled in the early 2000s by Paul Myhill and refined by Joe McCord, a biochemist who had co-discovered superoxide dismutase in 1969. The design premise was a reaction against conventional antioxidant supplements: ingested antioxidants can neutralize only one reactive molecule each, whereas a single induced enzyme molecule disposes of many per second. Ingredients were chosen from published reports of enzyme induction in rodents, each set at a dose low enough to avoid its own pharmacological effects (Nelson et al., 2006). That reasoning is why the blend came to be considered for health optimization at all.

The 2006 human study — uncontrolled, 29 subjects — reported a 40% fall in a blood marker of fat oxidation, and became the commercial foundation. The strongest later finding came from the National Institute on Aging Interventions Testing Program, which found longer median survival in male mice only (Strong et al., 2016). Independent controlled human trials, by contrast, found no effect. Rather than any single result overturning the earlier work, what changed was the type of evidence available: an uncontrolled marker study gave way to controlled trials measuring outcomes, and the marker findings did not replicate while the animal longevity signal did hold within its own program.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the class of evidence that would be required — a human clinical endpoint or a validated clinical surrogate moved in more than one trial — does not exist for this blend, since the only positive human findings are unvalidated redox biomarkers from a single uncontrolled study.

Medium 🟩 🟩

No benefit reaches Medium either: the same class of evidence, a clinical endpoint or validated surrogate in one good trial or in consistent observational data, is absent; the controlled human trials of the blend measured such endpoints and found no effect.

Low 🟩

Reduced Inflammatory Markers ⚠️ Conflicted

Sixty-six trials of curcumin alone, not the blend, lower C-reactive protein (CRP, a marker of inflammation) (Dehzad et al., 2023). The blend supplies roughly 71 mg of curcuminoids; the one study measuring CRP on it found nothing (Nelson et al., 2006). Net reading: not established at this dose.

Magnitude: For curcumin alone, CRP fell by 0.58 mg/L (95% confidence interval, or CI, the range within which the true value probably lies: −0.74 to −0.41); on the blend, no CRP change was observed.

Liver Enzyme Support

Forty-one trials of silymarin alone, not the blend, lower alanine aminotransferase (an enzyme that rises when liver cells are stressed), mainly at higher doses (Mohammadi et al., 2024). The blend delivers about 180 mg daily, at the low end of studied intakes. No blend trial measured this.

Magnitude: Direction only — for silymarin alone, alanine aminotransferase falls, and the reduction concentrates at higher doses and at durations of 12 weeks or more; the literature reports no outcome figure for the blend, since no trial of it has measured liver enzymes.

Stress and Anxiety Reduction

Trials of ashwagandha alone, not the blend, lower scores on validated anxiety and stress scales (Akhgarjand et al., 2022). The blend supplies 150 mg of root powder, not the 300–600 mg extracts used there. The one blend trial measuring quality of life found no difference (Ueberschlag et al., 2016).

Magnitude: For ashwagandha alone, anxiety fell by a standardised mean difference (SMD, the size of an effect expressed in units of the outcome’s own spread) of −1.55 (95% CI −2.37 to −0.74) with low certainty; no equivalent figure exists for the blend.

Working Memory Support

Across 29 trials of bacopa alone, not the blend, working and short-term memory improved only at 600 mg per day or more (Tiemtad et al., 2026). The blend supplies 150 mg of bacopa extract, a quarter of that threshold. No blend trial measured cognition.

Magnitude: For high-dose bacopa alone, working memory improved by a standardised mean difference of 2.03 against placebo (95% CI 1.28–2.78); the blend’s dose falls below the threshold at which any effect was seen.

Speculative 🟨

Maintained Muscle Protein Synthesis in Older Adults

The blend itself was tested, not one agent. Six weeks with milk protein preserved contractile protein synthesis while mitochondrial and cytoplasmic rates fell below control (Konopka et al., 2017). An unvalidated tissue biomarker, not function.

Shift in Blood Redox Markers ⚠️ Conflicted

These trials tested the blend, not one agent. An uncontrolled study reported lipid peroxidation down 40% (Nelson et al., 2006); controlled trials found nothing (Ueberschlag et al., 2016). Net reading: nothing survives placebo control.

Extended Median Lifespan in Male Mice

The blend was fed, not one agent. In a three-site federal mouse program, lifelong feeding raised median lifespan in males only, by roughly 7% (Strong et al., 2016). Animal data; no human lifespan evidence.

Chemoprevention in Mouse Skin Carcinogenesis

The blend was fed, not one agent. In a chemically induced mouse skin-tumour model it cut tumour incidence 33% and tumours per animal 57% (Liu et al., 2009). Animal data; no human cancer outcome.

Cartilage Protection in Osteoarthritis

The blend was tested, not one agent. It blocked cartilage-degrading signals in human osteoarthritic cartilage cells, and joint injection lowered damage scores in mice with surgically induced arthritis (Abusarah et al., 2017). Not oral dosing.

Vascular Protection

The blend was given, not one agent. In salt-fed rats it preserved vessel function and capillary density (Priestley et al., 2019); human vein and heart-cell work is in isolated tissue only. No human outcome.

Neuroprotection

The blend was tested, not one agent. It protected cultured oligodendrocytes (the cells that insulate nerve fibres) against oxidative damage (Lim et al., 2016). Cell work only; no human neurological outcome.

Benefit-Modifying Factors

  • Baseline oxidative burden: Marker improvement appeared only in an uncontrolled cohort with a strong age-related rise in lipid peroxidation at baseline (Nelson et al., 2006). A low baseline leaves less room for a measurable shift.

  • Age: Runners aged 35 and over showed a two-fold greater rise in superoxide dismutase than placebo, while the whole group was null (Ueberschlag et al., 2016). At the older end of the target range, the one trial found mixed tissue responses (Konopka et al., 2017).

  • Sex: The mouse longevity gain was confined to males (Strong et al., 2016). Whether that difference carries into humans is untested, and no human trial has reported results split by sex.

  • Pre-existing conditions: In alcohol use disorder, where oxidative stress is elevated, the blend still produced no benefit (Burnham et al., 2012), so disease-driven elevation does not appear to unlock a response.

  • Genetic polymorphisms: NQO1 and GSTM1 variants (genes coding for detoxifying enzymes downstream of the target pathway) alter how strongly cells respond to pathway activators. No study has stratified blend responses by these variants, so the influence remains untested.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the class of evidence required — a documented adverse event or clinical endpoint in more than one trial — does not exist, because the published human trials of the blend reported no adverse events at all, and the component-level signals come from spontaneous case reports and registry series rather than from trials.

Medium 🟥 🟥

Herb-Induced Liver Injury

Two of the five ingredients carry registry-grade liver signals, both established for the single agent rather than the blend. Ashwagandha produced five cases of cholestatic (obstructed bile flow) or mixed liver injury with jaundice and itching in a joint Icelandic and US Drug-Induced Liver Injury Network series (Björnsson et al., 2020). Green tea extract is among the most frequently implicated herbal products in liver injury (Ballotin et al., 2021). The blend’s doses of both sit far below the implicated intakes.

Magnitude: For ashwagandha alone, all five cases developed jaundice after 2–12 weeks, none progressed to liver failure, and liver tests normalised within 1–5 months in the four patients followed up. Across 936 herb-injury cases of all kinds, 82.8% recovered completely, 6.6% required transplantation and 10.4% died; the blend supplies roughly 74 mg of green tea polyphenols daily.

Low 🟥

Gastrointestinal Intolerance and Rash

These reports concern the blend, not one agent. The only user-level data are one physician-distributor’s informal estimate of loose stools and rash, relayed in a review by a volunteer group earning no product revenue (ALSUntangled Group, 2015). Uncontrolled self-report; no deaths or hospitalisations found.

Magnitude: Roughly 8% of about 18,000 users were estimated to have had side effects, chiefly loose stools and rash; the estimate is a single physician’s recollection, not a systematic tally.

Rise in Serum Uric Acid

This was seen with the blend itself, not a single agent: the founding uncontrolled study reported a non-significant rise in serum uric acid (Nelson et al., 2006). It matters for anyone with gout (arthritis triggered by uric acid crystals). No later trial re-measured it.

Magnitude: Direction only — serum uric acid rose across 120 days of uncontrolled supplementation in 29 adults, the change falling short of statistical significance; the literature reports no outcome figure, since the size of the shift was never published and no controlled trial has re-measured it.

Thyroid Hormone Elevation

Pooled randomised trials of ashwagandha alone, not the blend, show a modest rise in thyroxine without change in thyroid-stimulating hormone (Fornalik et al., 2026). At the blend’s 150 mg of root powder the shift is likely negligible, but directionally relevant on thyroid replacement.

Magnitude: For ashwagandha alone, thyroxine rose by 0.61 µg/dL (p = 0.02 — a 2% probability that a result this large arose by chance alone) across 23 trials; no thyroid measure has been reported in any trial of the blend.

Speculative 🟨

Tumour Cytoprotection from Sustained Pathway Activation

The targeted pathway is constitutively switched on in many tumours, conferring resistance to chemotherapy (Wang et al., 2008). Mechanistic concern for the blend, not one agent; no human data link it to tumour progression.

Interference with Exercise-Induced Adaptation ⚠️ Conflicted

Conventional antioxidants can blunt training adaptations. In exercising rats the blend did not, while vitamin C did (Bruns et al., 2018); the blend was tested, not one agent. Net reading: the comparison contradicts the concern.

Immune Activation in Autoimmune Disease

Ashwagandha alone, not the blend, is described as immunostimulating, which the herbal literature treats as relevant in autoimmune conditions. The basis is mechanistic and from isolated reports; no controlled human data exist at this dose.

Risk-Modifying Factors

  • Pre-existing liver disease: Active hepatitis, cirrhosis or unexplained enzyme elevation raises the consequence of ingredient-level liver signals. The registered liver trial excluded stage III–IV fibrosis for this reason (NCT00977730).

  • Baseline biomarkers: Elevated alanine aminotransferase, alkaline phosphatase (a bile-flow enzyme) or bilirubin before starting removes the ability to attribute any later rise to the supplement, and raises the chance that a rise is clinically meaningful.

  • Genetic polymorphisms: UGT1A1 variants (the gene for the enzyme that attaches sugars to bilirubin and catechins; Gilbert syndrome is the common harmless form) slow clearance, raising exposure. CYP2C9 variants (a liver drug-clearing enzyme) alter silymarin-sensitive clearance. Neither is studied here.

  • Sex: No sex-based safety difference is established for the blend. The mouse work showed sex-divergent responses (Strong et al., 2016), but no human trial has reported safety outcomes separately by sex.

  • Age: Older users take more medicines and carry more baseline liver and kidney impairment, widening the interaction surface described below. At the older end of the target range, slower clearance raises ingredient exposure at the same dose.

Key Interactions & Contraindications

  • Narrow-therapeutic-index drugs (tacrolimus, ciclosporin, some statins) cleared by CYP3A4 (the liver enzyme that breaks down most medicines): Caution. Curcumin and silymarin inhibit it in vitro, which could raise drug levels toward toxicity. The mitigation is 3–4 hours of dose separation with drug-level monitoring.

  • Warfarin and other vitamin K antagonists: Caution. Silymarin and curcumin inhibit CYP2C9, the enzyme clearing warfarin, and curcumin has mild antiplatelet activity (reduced clot formation); the consequence is increased bleeding risk. The mitigation is a clotting-ratio check within 1–2 weeks of starting or stopping.

  • Nadolol and other OATP-transported beta-blockers: Caution. Green tea catechins block OATP1A2 (an intestinal uptake transporter), cutting nadolol absorption and blood-pressure control. The mitigation is at least four hours between the supplement and the beta-blocker.

  • Levothyroxine and antithyroid drugs (carbimazole, methimazole): Monitor. Ashwagandha modestly raises thyroxine, which can add to replacement therapy or oppose antithyroid treatment. The mitigation is a thyroid-stimulating hormone and free thyroxine recheck three months after starting.

  • Iron supplements and iron-deficiency treatment: Caution. Curcumin and green tea catechins both chelate non-haem iron in the gut, reducing absorption and potentially worsening deficiency. The mitigation is at least two hours between iron and the supplement.

  • Over-the-counter paracetamol and high-dose non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac): Caution. Both burden the liver, compounding the ingredient-level liver signals. The mitigation is avoiding sustained concurrent high-dose use, with the supplement stopped if liver symptoms appear.

  • Other supplements with the same targets (sulforaphane, standalone curcumin, standalone green tea extract, standalone ashwagandha): Caution. These are additive on the same pathway, and stacking standalone green tea extract pushes catechin intake toward the liver-injury range. The mitigation is dropping the overlapping standalone product.

  • Additive sedatives (valerian, magnesium glycinate, melatonin, standalone ashwagandha): Caution. Ashwagandha and bacopa both have mild calming effects, so combined evening dosing can produce additive drowsiness. The mitigation is reducing one component rather than both, or morning dosing.

  • Other interventions — chemotherapy and radiotherapy: Absolute contraindication during active treatment. Pathway activation protects tumour cells as well as healthy ones, and high-dose antioxidant use during cancer treatment is conventionally avoided. The mitigation is resumption no sooner than 30 days after treatment ends.

Populations who should avoid Protandim:

  • Anyone with active liver disease, or alanine aminotransferase or aspartate aminotransferase (a second liver-injury enzyme) above three times the upper limit of normal, or total bilirubin above 2.0 mg/dL
  • Anyone with stage III or IV liver fibrosis, or Child-Pugh Class B or C cirrhosis (a severity grading for chronic liver disease)
  • People undergoing active chemotherapy or radiotherapy, and for at least 30 days afterwards
  • Pregnant and breastfeeding women — ashwagandha is traditionally regarded as abortifacient (able to cause miscarriage) and no safety data exist
  • Anyone with an untreated overactive thyroid, or thyroid-stimulating hormone below 0.4 mIU/L
  • Children and adolescents under 18, in whom the blend has never been studied

Risk Mitigation Strategies

  • Baseline liver panel before the first dose: Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and bilirubin are measured first. Without a baseline, an enzyme rise cannot be attributed, which is the core difficulty in herb-induced liver injury.

  • Liver enzyme recheck at 8–12 weeks: Reported liver injury from these ingredients has a latency of 2–12 weeks, so a single check inside that window catches most cases before jaundice appears.

  • Dosing with food rather than on an empty stomach: Fasted dosing sharply raises catechin absorption and is the main modifiable driver of green tea extract liver injury. Food also reduces the reported loose stools.

  • Immediate stop on liver symptoms: Dark urine, yellowing of skin or eyes, right-upper-abdominal pain, unexplained itching or persistent nausea warrant stopping and a same-week liver panel, since the reported injury resolves on withdrawal.

  • Keeping total ingredient exposure inside one product: Stacking standalone green tea extract, curcumin or ashwagandha on top multiplies catechin and withanolide (ashwagandha’s active compound) intake several-fold into the range where liver injury has been reported.

  • Holding around cancer treatment and elective surgery: A stop at least 14 days before surgery covers curcumin’s antiplatelet effect, and the blend is avoided entirely during chemotherapy or radiotherapy because pathway activation protects tumour cells.

  • Uric acid check where gout is in the history: Measurement at baseline and at three months. The one study reporting the direction found a rise, and an attack is both avoidable and easy to misattribute.

Therapeutic Protocol

  • Standard dose: One 675 mg caplet daily, supplying 225 mg milk thistle extract (80% silymarin), 150 mg bacopa extract (45% bacosides), 150 mg ashwagandha root powder, 75 mg green tea extract (98% polyphenols) and 75 mg turmeric extract (95% curcumin).

  • Higher-dose alternative: The one placebo-controlled inpatient trial (Burnham et al., 2012) used 1,350 mg daily, two caplets, for seven days without adverse events. No efficacy advantage was demonstrated, so the higher dose has no evidential support beyond tolerability.

  • Competing approach — single high-dose agents: Practitioners who follow the trial literature instead give each plant at its own studied dose, typically 500–1,000 mg curcumin with piperine and 300–600 mg ashwagandha extract. Neither approach is the default.

  • Competing approach — dietary pathway activators: Sulforaphane from broccoli sprouts is the pathway activator with the largest independent human dataset, favoured by researchers who regard the blend’s cell-culture synergy as unproven in people.

  • Origin of each approach: The fixed low-dose blend traces to Joe McCord and the manufacturer; the single-agent high-dose approach comes from the individual trial literature; the sulforaphane route is associated with Johns Hopkins chemoprevention researchers.

  • Best time of day: Morning, with a meal containing fat. Food is required to limit catechin absorption spikes, fat aids curcumin and silymarin uptake, and morning dosing keeps the two mildly calming ingredients clear of other evening sedatives.

  • Half-life: Short for every component — curcumin and silymarin clear within 2–8 hours, catechins within 3–5 hours. Enzyme induction lasts far longer than the compounds, which is why once-daily dosing is coherent.

  • Single versus split dosing: All trials used a single daily dose, and pathway induction persists for 24–48 hours, so splitting offers no established advantage. Splitting is used only to manage loose stools.

  • Genetic polymorphisms: UGT1A1 and CYP2C9 variants alter conjugation and clearance of the catechin and silymarin fractions and could shift effective exposure. No pharmacogenetic dosing guidance exists; testing is not currently actionable here.

  • Sex-based differences: The only longevity signal was male-specific and the only marker signal was age-specific, not sex-specific. No human trial has published dose or response data split by sex, so dosing is not differentiated.

  • Age-related considerations: The single positive subgroup was aged 35 and over. At the older end of the target range, reduced conjugating capacity raises exposure at a fixed dose, which argues for the 675 mg dose rather than the doubled one.

  • Baseline biomarkers: Elevated lipid-peroxidation markers or inflammatory markers before starting define what response, if any, can be observed. Normal baseline values leave nothing measurable to move.

  • Pre-existing conditions: Liver disease, gout, thyroid disorders and active cancer treatment all change the risk-benefit calculation and are addressed under contraindications rather than by dose adjustment.

Discontinuation & Cycling

  • Intended duration: Marketed for continuous indefinite use. The longest controlled human exposure on record is 90 days, and the longest registered one year, so beyond a year there is no human safety or efficacy data at all.

  • Stopping the agents: The blend is a single fixed product, so all five agents stop together; there is no mechanism for tapering one and continuing the others short of switching to separate single-ingredient products.

  • Withdrawal effects: None reported. Enzyme induction is transcriptional and decays over days as the inducing compounds clear, so the expected result of stopping is a gradual return to baseline rather than rebound.

  • Tapering: Not applicable. No trial used a taper, no withdrawal syndrome is described, and abrupt cessation was used in every study, including the seven-day inpatient trial.

  • Cycling: Not established either way. Cell work shows the pathway response is dose- and time-dependent and can attenuate, which is the theoretical argument for cycling, but no human study has compared continuous with intermittent use.

  • Stopping to test effect: Because no validated response marker exists, a 4-week stop and restart is the only practical way to distinguish a real subjective effect from expectancy, and it carries no known withdrawal risk.

Sourcing and Quality

  • Single-source product: The blend is a patented formulation available only from the manufacturer and its distributors; the ingredient ratio is proprietary, so there is no generic equivalent and no competing brand to compare against.

  • Proprietary blend disclosure: The label states only the 675 mg total. The per-ingredient amounts come from the patent and are published independently by ConsumerLab, which is the only way to verify what a dose actually contains.

  • Third-party testing: No independent certification mark is carried. What remains verifiable is a per-lot certificate of analysis covering identity, heavy metals, pesticide residues and microbial limits — the four contaminant classes that matter most for imported botanical extracts.

  • Documented quality failure: In December 2012 the manufacturer voluntarily recalled US and Japanese lots produced between July and November 2012 for possible metal fragment contamination — a manufacturing rather than formulation failure, but a relevant record.

  • Ingredient forms to check: Milk thistle standardised to 80% silymarin, bacopa to 45% bacosides, green tea to 98% polyphenols and turmeric to 95% curcuminoids. Unstandardised botanical powders deliver a fraction of these actives.

  • Ashwagandha form: The blend uses root powder rather than a standardised extract. Root powder is the traditional material, but its withanolide content varies far more between lots than a standardised extract’s.

  • Buying the ingredients separately: Each plant is available individually at a fraction of the cost and at the doses actually used in trials, though no separate combination reproduces the patented ratio.

Practical Considerations

  • Time to effect: No subjectively noticeable effect is expected. The marker changes reported took 30 days for lipid peroxidation and 120 days for enzyme induction; controlled trials at 7, 42 and 90 days found no functional change.

  • Common pitfall — trusting the headline claim: The “40% reduction in oxidative stress in 30 days” figure comes from a single uncontrolled study whose marker findings failed to replicate under placebo control in two later trials.

  • Common pitfall — assuming ingredient benefits transfer: Four of the five plants have substantial trial literatures at doses three to ten times higher than the blend delivers. Those results cannot be assumed to apply at this dose.

  • Common pitfall — fasted dosing: Taking it on an empty stomach for “better absorption” is the single change most likely to convert a safe catechin dose into a risky one.

  • Regulatory status: Sold as a dietary supplement, which means no pre-market efficacy review. In April 2017 the FDA issued a warning letter over disease claims that made the product an unapproved drug.

  • Cost and access: About $50 per month direct from the manufacturer or its distributors, roughly three to five times the cost of buying the five ingredients separately at higher doses. Availability is otherwise unrestricted.

  • No payer involvement either way: Neither the blend nor its separate ingredients are reimbursed by insurers or health systems, so no institutional payer has a financial incentive favouring one — removing a common source of structural bias, but leaving no payer-funded comparative trial.

Interaction with Foundational Habits

  • Sleep: Indirect and mild. Ashwagandha and bacopa are both mildly calming, and the trace caffeine from green tea extract is 1.8 mg per dose, too small to disturb sleep. The practical consideration is timing: morning dosing avoids the calming ingredients adding to evening sedation from other supplements.

  • Nutrition: Direct and consequential. Food is required, not optional, since fasted dosing drives the catechin absorption spike behind green tea extract liver injury. A meal containing fat also improves curcumin and silymarin uptake. A two-hour gap from iron-rich meals or iron supplements applies, since curcumin and catechins chelate non-haem iron.

  • Exercise: Potentially blunting in theory, but not observed. Conventional antioxidants can suppress training adaptations by dampening the reactive signalling that drives them. In exercising rats, the blend permitted mitochondrial adaptation while vitamin C did not (Bruns et al., 2018). Morning dosing separates it from afternoon training.

  • Stress management: Indirect and strengthening. Pooled trials of ashwagandha at higher doses lower cortisol (Fornalik et al., 2026), so the blend’s direction aligns with stress-reduction practices rather than opposing them. At 150 mg of root powder the contribution is likely small, and no blend trial has measured cortisol or perceived stress.

Monitoring Protocol & Defining Success

Because no validated response marker exists for this blend, monitoring is built around safety rather than efficacy. Before the first dose, the baseline set is a liver panel covering alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase (a bile-duct enzyme) and total bilirubin, plus serum uric acid, high-sensitivity C-reactive protein, thyroid-stimulating hormone with free thyroxine, and ferritin. These fix the reference point against which any later change is judged — the central difficulty in attributing herbal liver injury. Ongoing testing follows a simple cadence: the liver panel and uric acid are repeated at 8–12 weeks, covering the reported latency window for liver injury; the full panel is repeated at 6 months; testing then continues every 6–12 months while use continues. Success is defined by absence of drift, not by expected improvement.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Alanine aminotransferase 10–20 U/L (men), 8–17 U/L (women) Most sensitive marker of liver cell injury ALT = alanine aminotransferase. Conventional labs flag only above 40–55 U/L, so a doubling inside the “normal” range is easily missed. Fasting not required
Aspartate aminotransferase 10–20 U/L Pairs with ALT to separate liver from muscle origin AST = aspartate aminotransferase. Conventional labs flag only above 35–40 U/L. Also rises after hard exercise, so a result within 48 hours of heavy training is unreliable
Alkaline phosphatase 50–90 U/L Detects the cholestatic pattern seen in ashwagandha liver injury ALP = alkaline phosphatase. Conventional upper limit is 120–130 U/L. Rises in bone disease too; gamma-glutamyl transferase pairs with it to confirm liver origin
Gamma-glutamyl transferase Under 20 U/L Confirms that a raised ALP is of liver origin GGT = gamma-glutamyl transferase, a bile-duct enzyme. Conventional upper limit is 55–65 U/L (men) and 35–45 U/L (women). Sensitive to alcohol intake, which is recorded alongside the result
Total bilirubin 0.3–1.0 mg/dL Detects the jaundice that defined every reported ashwagandha case Gilbert syndrome, a common benign UGT1A1 variant, raises baseline bilirubin without disease and is relevant where present
Serum uric acid 3.5–5.5 mg/dL (men), 3.0–5.0 mg/dL (women) The one blend-specific signal reported, and directly actionable in gout Conventional cut-off is 7.0 mg/dL. Requires an 8-hour fast and 24 hours without alcohol before testing
High-sensitivity C-reactive protein Under 0.5 mg/L The inflammatory outcome the blend is marketed to improve hs-CRP = high-sensitivity C-reactive protein. Conventional “low risk” is under 1.0 mg/L. Invalid within 2 weeks of infection or injury
Thyroid-stimulating hormone 0.5–2.0 mIU/L Ashwagandha shifts thyroid hormone modestly TSH = thyroid-stimulating hormone, the pituitary signal to the thyroid. Conventional range extends to 4.5 mIU/L. A morning draw is standard
Free thyroxine 1.0–1.5 ng/dL The specific hormone shown to rise with ashwagandha Free thyroxine is the unbound, active fraction. Conventional range is wider, 0.8–1.8 ng/dL. Best paired with TSH in the same draw
Ferritin 50–150 ng/mL (men), 30–120 ng/mL (women) Curcumin and catechins chelate iron and can deepen a deficiency Ferritin is the iron storage protein. Conventional range is far wider, roughly 24–336 ng/mL (men) and 11–307 ng/mL (women). Falsely elevated by inflammation, so it is read alongside hs-CRP

Qualitative markers, recorded deliberately rather than recalled:

  • Digestive tolerance — stool consistency and frequency in the first four weeks, the most commonly reported complaint
  • Skin — any new rash, the second reported complaint
  • Energy and exercise recovery — perceived recovery between hard sessions, rated weekly on a fixed scale
  • Cognitive clarity and working memory — tracked only against a fixed self-rating, since no cognitive outcome has been measured in any trial
  • Sleep quality and duration — relevant because two ingredients are mildly calming
  • Early liver symptoms — dark urine, itching, yellowing of skin or eyes, persistent nausea, right-upper-abdominal discomfort

Emerging Research

  • Unreported liver trial: NCT00977730 randomised 70 adults with biopsy-proven fatty liver inflammation to 675 mg daily or placebo for 12 months, scoring liver injury on repeat biopsy. It completed in 2011 and no results were ever posted — the largest and longest controlled test of the blend.

  • Personalised neurology pilot: NCT06429059 assigned the blend for six months to the oxidative-stress subgroup of 50 participants with motor neuron disease, tracking a validated function scale and a blood marker of nerve damage. Completed 2025 at Duke and Temple; results submitted in 2026 but not yet posted.

  • A weakening signal: Semanchik et al., 2026 fed up to six times the human dose to mature sedentary horses for 56 days and found no effect on antioxidant or inflammatory status, echoing the null human trials. Notably, manufacturer staff co-authored this negative result.

  • A strengthening signal: Wahl et al., 2021 found the blend among healthy-aging interventions that suppress repetitive-element transcripts (dormant genetic sequences that reawaken with age) in mice, alongside calorie restriction and rapamycin — an aging mechanism independent of antioxidant markers.

  • Absorption data gap in humans: Song et al., 2019 tracked the blend’s catechin, silibinin and curcumin in rats and found them concentrated in the small intestine without accumulation. No equivalent human data exist, leaving the tissue exposure question open.

  • Dose-response question: Whether 675 mg daily delivers enough of each extract to reproduce single-agent effects is untested. The silymarin dose-response analysis of Mohammadi et al., 2024 found benefits concentrated at higher intakes, which would predict a null result at this dose.

Conclusion

Protandim is a fixed five-plant blend taken as a single daily oral dose. It rests on a different idea from ordinary antioxidant supplements: rather than supplying molecules that soak up damaging compounds, it is meant to prompt cells to build more of their own protective enzymes. The laboratory case for that idea is coherent, and the five plants together do appear to press the intended cellular switch harder than any one of them alone.

What has not followed is benefit in people. The blend moved blood markers of oxidative wear in one uncontrolled study; the controlled trials that followed found almost nothing beyond scattered shifts in single measures. Nothing published shows it changes how a person feels, functions or how long they live. The animal life-extension finding was genuine but modest, limited to males, and stands alone.

Safety looks unremarkable at the marketed dose. Reported complaints are digestive and skin-related, and each plant is present at a small fraction of the amount at which it has caused liver injury alone. Those same small amounts sit well below the doses in the trials supporting each plant, so single-plant benefits cannot be assumed to carry over.

Much of the supporting work was produced by people with a direct commercial stake in the product, and regulators have challenged the disease claims made around it. The outside groups that have appraised it earn nothing either way, and their verdicts are small, short and largely negative. The evidence base is thin and lopsided.

Top - Benefits - Risks - Protocol